Literature DB >> 11414465

Application of yeast enolase as antigen for immunodiagnosis of malaria.

K Sato1, S Kano, Y Matsumoto, R Glanarongran, S Krudsood, S Looareesuwan, M Aikawa, M Suzuki.   

Abstract

In 1998, we reported that Plasmodium falciparum (Pf) enolase was useful as the capture antigen for the immunodiagnosis of malaria. In the present study, we modified a fluorescence-ELISA for the diagnosis of malaria by applying yeast enolase or rabbit muscle enolase as antigen. Sera from 67 falciparum malaria patients and 15 vivax malaria patients were tested by the method. Positivity rates of the former was 82.1% against yeast enolase antigen and 90.5% against rabbit muscle enolase antigen, and those of latter was 93.3% against both enolase antigens. Mean antibody level (RFU values) of sera from falciparum and vivax malaria patients were significantly higher than those from healthy individuals. There was a significant correlation between anti-yeast and anti-rabbit muscle enolase antibody level (RFU values) in the group of falciparum subjects (r = 0.401, p<0.001). A significant correlation between RFU values against yeast enolase antigen and indirect fluorescent antibody titers against crude Pf antigen in the same subjects was recognized (r = 0.518, p<0.001). Longitudinal changes of RFU values against yeast enolase for the following 4 weeks after admission were also examined for sera from falciparum malaria patients. Patients with more severe malaria showed increasing RFU values as the clinical courses progressed. However, in the mild cases, each RFU value stayed unchanged during the course. We concluded that yeast and rabbit muscle enolase could be appropriately used as antigen for the immunodiagnosis of malaria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11414465

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  7 in total

Review 1.  Surface-expressed enolases of Plasmodium and other pathogens.

Authors:  Anil Kumar Ghosh; Marcelo Jacobs-Lorena
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  Plasmodium ookinetes coopt mammalian plasminogen to invade the mosquito midgut.

Authors:  Anil K Ghosh; Isabelle Coppens; Henrik Gårdsvoll; Michael Ploug; Marcelo Jacobs-Lorena
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

3.  Production of Plasmodium vivax enolase in Escherichia coli and its protective properties.

Authors:  Chao Zhang; Yaping Gu; Jianxia Tang; Feng Lu; Yuanyuan Cao; Huayun Zhou; Guoding Zhu; Jun Cao; Qi Gao
Journal:  Hum Vaccin Immunother       Date:  2016-08-03       Impact factor: 3.452

4.  Leucine aminopeptidase is an immunodominant antigen of Fasciola hepatica excretory and secretory products in human infections.

Authors:  A Marcilla; J E De la Rubia; J Sotillo; D Bernal; C Carmona; Z Villavicencio; D Acosta; J Tort; F J Bornay; J G Esteban; R Toledo
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

5.  Protective properties and surface localization of Plasmodium falciparum enolase.

Authors:  Ipsita Pal-Bhowmick; Monika Mehta; Isabelle Coppens; Shobhona Sharma; Gotam K Jarori
Journal:  Infect Immun       Date:  2007-09-04       Impact factor: 3.441

6.  Complete Molecular and Immunoprotective Characterization of Babesia microti Enolase.

Authors:  Xiangye Liu; Chen Zheng; Xiaoge Gao; Jiaxu Chen; Kuiyang Zheng
Journal:  Front Microbiol       Date:  2017-04-11       Impact factor: 5.640

7.  Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.

Authors:  Reema Gupta; Vikash Kumar; Pramod Kumar Kushawaha; Chandradev Pati Tripathi; Sumit Joshi; Amogh Anant Sahasrabuddhe; Kalyan Mitra; Shyam Sundar; Mohammad Imran Siddiqi; Anuradha Dube
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.